Bulk RNA sequencing was used to analyze tumors and matching germline DNA samples in 40 patients

Although neoadjuvant chemoradiotherapy treatment followed by surgical resection is the recommended treatment for locally advanced rectal cancer (LARC), response rates remain poor. In proficient mismatch repair (pMMR) rectal cancer, combination (vs. monotherapy) immunotherapy has begun to show promise. This study involved 87 LARC patients undergoing short-course radiotherapy (SCRT), followed by CAPOX (capecitabine and oxaliplatin), in combination with the immune checkpoint inhibitor tislelizumab. here was the bulk RNA sequencing of 40 patients used to analyze tumors and matching germline DNA samples